Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance.

Laura A. Kirkman, Wenhu Zhan, Joseph Visone, Alexis Dziedziech, Pradeep K. Singh, Hao Fan, Xinran Tong, Igor Bruzual, Ryoma Hara, Masanori Kawasaki, Toshihiro Imaeda, Rei Okamoto, Kenjiro Sato, Mayako Michino, Elena Fernandez Alvaro, Liselle F. Guiang, Laura M. Sanz, Daniel J Mota, Kavitha Govindasamy, Rong WangYan Ling, Patrick K. Tumwebaze, George Sukenick, Lei Shi, Jeremie Vendome, Purnima Bhanot, Philip J. Rosenthal, Kazuyoshi Aso, Michael A. Foley, Roland A. Cooper, Bjorn Kafsack, J Stone Doggett, Carl F. Nathan, Gang Lin

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalDefault journal
Volume115
DOIs
StatePublished - Jul 17 2018

Keywords

  • Antimalarials
  • Artemisinins
  • Bortezomib
  • Drug Resistance
  • Microbial
  • Humans
  • Lactones
  • Oligopeptides
  • Plasmodium falciparum
  • Proteasome Endopeptidase Complex
  • Proteasome Inhibitors
  • Protozoan Proteins

Disciplines

  • Life Sciences
  • Medicinal and Pharmaceutical Chemistry
  • Parasitic Diseases

Cite this